Did You Know...
...that when IBM conducted a market study of Chester Carlson's invention in 1959, the company concluded that it would take only 5000 units of his new product to saturate the market? IBM therefore declined to be part of the new product introduction. Too bad for IBM. Carlson's invention was the xerography process, and his new product was the beginning of the Xerox Corporation. It is estimated that every day, worldwide, 3,000,000,000 copies are made!!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8119590 | Prevention and treatment of restenosis by local administration of drug Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally before or during bypass surgery on disea... | 02/21/2012 |
| 7968126 | Creation of a biological atrioventricular bypass to compensate for atrioventricular block A method of creating an atrioventricular bypass tract for a heart comprises growing mesenchymal stem cells into a strip with two ends, attaching one end of the strip onto the atrium of the heart, and attaching the other end of the strip to the ventricle of the heart... | 06/28/2011 |
| 7196093 | Reversible inhibitors of SAH hydrolase and uses thereof 1. The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowe... | 03/27/2007 |
| 7144588 | Method of preventing surgical adhesions The present invention relates to a method and composition for preventing surgical adhesions during surgery. Tissue surfaces and/or surgical articles involved in the surgery are separated by a biomaterial provided in the form of a non-crosslinked, decellularized and ... | 12/05/2006 |
| 7067276 | Method of using metaloporphyrins for treatment of arteriosclerotic lesions A method for treating arteriosclerotic lesions is provided wherein the method is characterized by administering a chemical compound to the patient, the compound being a porphyrin complexed with a radioactive metal. Cells which exhibit an affinity for the porphyrin e... | 06/27/2006 |
| 7022348 | Method of creating biological and biosynthetic material for implantation A method of creating an implantation material from biological and tissue engineered biosynthetic and biological tissue of autogenic, allogenic and xenogenic origin suitable for implantation into humans or animals as surgical and vascular prostheses. The resultant ma... | 04/04/2006 |
| 7015209 | Hair-growing agent A hair-growing agent comprising, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even ... | 03/21/2006 |
| 6936437 | Methods and compositions for production of recombinant peptides This invention provides a method for solubilizing and recovering in bioactive form, a target polypeptide or protein that has been expressed from a host organism in insoluble form. The polypeptide is isolated from the host organism by standard procedures including di... | 08/30/2005 |
| 6933278 | Treatment of hypertension using growth hormone in mammals subjected to fetal programming Embodiments of this invention include methods for decreasing hypertension in mammals subjected to adverse cardiovascular fetal programming or a long-term adverse postnatal environment. Fetal programming can result from adverse intrauterine conditions, including grow... | 08/23/2005 |
| 6881546 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor Methods and compositions are disclosed that are useful for the prevention and/or treatment of cardiovascular and cardiac diseases and disorders, or damage resulting from surgical or medical procedures that may cause ischemic or ischemic/reperfusion damage in humans;... | 04/19/2005 |
| 6849262 | Vascular coating composition This invention relates to methods of coating the lumenal surface of a blood vessel, or other tissue cavity, and to compositions suitable for use in same. ... | 02/01/2005 |
| 6790634 | Methods and compositions relating to phosphorylated myosin light chain 1 Two novel phosphorylation sites of myosin light chain 1 (MLC1) are described. Methods of monitoring phosphorylation of MLC1 to identify new cardiac and skeletal muscle protective agents, monitor the extent of preconditioning of cardiac and skele... | 09/14/2004 |
| 6690970 | Biological pacemaker and implantation catheter A biological pacemaker and implantation catheter for restoring normal or near normal heartbeat function without a mechanical pacemaker. The biological pacemaker is provided by a bridge of implantation cells, such as nerve cells, stem cells or ganglion cel... | 02/10/2004 |
| 6673832 | Methods for identifying compounds for treating pain The invention provides a method of determining whether a compound alleviates vasoconstriction-independent nerve pain mediated by endothelin-1 (ET-1). The method involves (i) determining whether the compound has the ability to inhibit a vasoconstriction-in... | 01/06/2004 |
| 6573061 | Sarcomere protein composition The present invention provides high throughput screening systems for identifying compounds that modulate the biological activity of a biochemically functional sarcomere. The method can be performed in plurality simultaneously with fluorescence or absorban... | 06/03/2003 |
| 6544946 | Inhibitors for use in hemostasis and immune function The present invention relates to polynucleotide and polypeptide molecules for use as inhibitors in hemostasis and immune function. Such inhibitors are members of the family of proteins bearing a collagen-like domain and a globular domain. The inhibitors a... | 04/08/2003 |
| 6537567 | Tissue-engineered tubular construct having circumferentially oriented smooth muscle cells Improved methods for the production of tissue-engineered constructs, including muscular tissue constructs such as vascular constructs, are disclosed. The methods include the use of improved substrates for cell growth, improved cell culture media for cell ... | 03/25/2003 |
| 6521244 | Body filling material A body filling agent is formed of a collagen in the form of powder, fiber or gel, and at least one kind of implantable particles selected from a group consisting of implantable polymer and pericardium. A mixture of the collagen and the implantable particl... | 02/18/2003 |
| 6503540 | Cloning and characterization of bves, a novel gene expressed in heart and uses thereof The present invention is directed to cloning and characterization of bves (blood vessel/epicardial substance), a cDNA expressed in developing and adult heart and skeletal muscle cells in chick, mouse and human. Also provided are applications of Bves as a ... | 01/07/2003 |
| 6479079 | Anticalcification treatments for fixed biomaterials A method for treating biomaterial is provided in which a biological tissue, typically after being cross-linked, is contacted with an anticalcification treatment solution under condition effective to render the biomaterial resistant to in vivo calcificatio... | 11/12/2002 |
| 6387369 | Cardiac muscle regeneration using mesenchymal stem cells Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a ... | 05/14/2002 |
| 6372229 | Vascular coating composition This invention relates to methods of coating the lumenal surface of a blood vessel, or other tissue cavity, and to compositions suitable for use in same.... | 04/16/2002 |
| 6368614 | Biological material, method of preparing such materials A biological material is prepared for use in ophthalmology by steps of providing animal pericardium, subjecting the animal pericardium to multiple steps of freezing and thawing in a salt solution and incubating the animal pericardium in a solution of ammo... | 04/09/2002 |
| 6368573 | Diagnostic uses of 2-substituted adenosine carboxamides The present invention discloses a method for measuring myocardial function in a mammal in need of such measurement by: a) administering 2-substituted adenosine carboxamide derivatives at a dosage rate of less than 1 μg/kg/min, preferably between about 0.... | 04/09/2002 |
| 6268336 | Pharmaceutical composition for treatment of hepatic diseases The present invention relates to a pharmaceutical composition for treatment of hepatic diseases which comprises erythropoietin as an active ingredient to reduce excess iron ions in the liver of a mammal with hepatic diseases, thus improving hepatic functi... | 07/31/2001 |
| 6248933 | Cellular basis of vascular-graft stenosis A mouse model for vein graft stenosis useful for identifying compounds which reduce or prevent such stenosis, consisting of a mouse engrafted with an autogenous vein which exhibits detectable stenosis within 30 days of transplantation. Also disclosed are ... | 06/19/2001 |
| 6238429 | Biologic cabling A length of living conductive cells may be injected directly or may be grown to be attached to a fibrous matrix of material that provides for flexible structure so as to deliver a stimulation signal from one end of the biologic cable to the other to induc... | 05/29/2001 |
| 6231879 | Biocompatible devices with foam scaffolds This invention is directed to methods of manufacturing implantable biocompatible cell encapsulation devices, wherein the cell encapsulation devices have a jacket made of a permeable, biocompatible material that is loaded with a core made of a reticulate f... | 05/15/2001 |
| 6203818 | Nutritional supplement for cardiovascular health A nutritional supplement for improving cardiovascular health via aiding in preventing, delaying the onset of and/or slowing the progression of atherosclerosis and coronary heart disease, the supplement comprising one or more flavonoids and folic acid or f... | 03/20/2001 |
| 6190916 | Troponin I composition The present invention relates to stable compositions useful as primary standards and calibrators and controls comprising a cardiac troponin I (cTnI) such as native, recombinant, addition and deletion forms thereof, whether or not complexed with other trop... | 02/20/2001 |
| 6165490 | Biological material, method of preparing such materials, uses thereof and products made therefrom A biological material is prepared for use in ophthalmology by steps of providing animal pericardium, subjecting the animal pericardium to multiple steps of freezing and thawing in a salt solution and incubating the animal pericardium in a solution of ammo... | 12/26/2000 |
| 6114180 | Synthetic calibrators for use in immunoassays, comprising the analytes or partial sequences thereof which are conjugated to inert carrier molecules The invention relates to synthetic calibrators for immunological tests, analyte-specific epitopes being coupled to other proteins or to synthetic carriers.... | 09/05/2000 |
| 6054142 | Biocompatible devices with foam scaffolds A biocompatible cell device having an internal foam scaffold to provide a growth surface for encapsulated cells which produce a biologically active molecule.... | 04/25/2000 |
| 5994300 | Vascular endothelial cell growth factor C subunit Vascular endothelial cell growth factor C subunit DNA is prepared by polymerase chain reaction techniques. The DNA encodes a protein that may exist as either a heterodimer or homodimer. The protein is a mammalian vascular endothelial cell mitogen and as s... | 11/30/1999 |
| 5919449 | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function Porcine cardiomyocytes and methods for using the cardiomyocytes to treat disorders characterized by insufficient cardiac function are described. The porcine cardiomyocytes are preferably embryonic porcine cardiomyocytes. The porcine cardiomyocytes can be ... | 07/06/1999 |
| 5851554 | Purified cardiac troponin I A method is provided for isolating substantially intact cardiac troponin I from cardiac tissue comprising extracting the, troponin I and purifying it in the presence of an effective amount of a mixture of protease inhibitors. The human cardiac troponin I ... | 12/22/1998 |
| 5733549 | Peptides including amino acid sequences selected from lipoprotein (a) and apolipoprotein (a), antibodies recognizing these amino acid sequences, and methods of determination using these antibodies Amino acid sequences having specificity as lipoprotein (a) and low homology with LDL and plasminogen are selected from the amino acid sequence of lipoprotein (a), and antibodies to lipoprotein (a) which recognize these amino acid sequences specifically ar... | 03/31/1998 |
| 5716787 | Immunological detection method for organ transplant rejection Antibodies that are indicative of organ transplant rejection, for example, cardiac or kidney transplant rejection, and of associated pathological conditions, for example, accelerated (or transplant-associated) coronary artery disease (CAD) are identified,... | 02/10/1998 |
| 5675062 | Cellular basis of transplant arteriosclerosis in mice A mouse model for transplant arteriosclerosis useful for identifying compounds which reduce or prevent such arteriosclerosis, consisting of a mouse engrafted with a histoincompatible artery which exhibits detectable arteriosclerosis within 30 days of tran... | 10/07/1997 |
| 5645587 | Prevention of calcification and degeneration of biological tissue grafts for implantation in humans The present invention relates to chemical treatment for prevention of calcification and degeneration of biological tissue grafts used as a whole or in a part as heart valve substitutes, substitutes of blood vessel, pericardial substitutes, and surgical me... | 07/08/1997 |
